GlobeNewswire Inc.··NaSagimet Biosciences Unveils MASH Trial Data, Secures Nasdaq Approval for Employee Equity Grant
Sagimet presented Phase 2b denifanstat data showing bile acid biomarker potential in MASH patients, while securing Nasdaq approval for employee stock options.
SGMTclinical trial dataMASH